Skip to main
  1. Stocks
  2. Alkermes
  3. Forecast
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 21%
Sell 7%
Strong Sell 0%

Bulls say

Alkermes is viewed favorably because its 3Q26 results beat expectations with $480.1M in revenue, 21.8% year-over-year growth, and strong proprietary product sales of $417.3M, while cash and investments of $787.6M support continued R&D. The core commercial base, including Lumryz, Vivitrol, Aristada, and Lybalvi, is generating durable cash flow and helping fund a growing neuroscience pipeline without sacrificing profitability, as management kept FY26 revenue guidance at $1.73B–$1.84B. Upbeat sentiment also reflects the orexin program, where encouraging alixorexton data in NT1, NT2, and idiopathic hypersomnia, plus upcoming readouts in year-end or early-’27 and 2027, could expand the franchise toward multi-billion-dollar revenue potential.

Bears say

Alkermes is facing a negative outlook because its earnings base is vulnerable to erosion in both royalty income and proprietary products, which could pressure profitability through the remainder of the decade. The injectable business also appears exposed to commercial headwinds and rapid competitive erosion, while significant Medicaid exposure adds reimbursement risk under the current administration. Meanwhile, the orexin program remains early stage and still needs larger-study validation of efficacy and safety, leaving the pipeline, FDA approval prospects, and the company’s heavy R&D and SG&A burden as meaningful fundamental risks.

Alkermes (ALKS) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 21% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Alkermes (ALKS) Analyst Forecast & Price Prediction

Get the latest Alkermes (ALKS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Alkermes (ALKS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 14 analysts, Alkermes (ALKS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.93, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.93, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Alkermes (ALKS) Analyst Forecast & Price Prediction

Get the latest Alkermes (ALKS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Alkermes (ALKS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ALKS stock data and trends